A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab in Adult Subjects With H-1 Antihistamine Refractory Chronic Spontaneous Urticaria

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002) in adult subjects with H-1 antihistamine refractory chronic spontaneous urticaria. Subjects who complete the randomized, double-blind, placebo-controlled treatment period may have the option to enroll in an open-label extension period and receive up to 6 doses of subcutaneous lirentelimab.

Start Date26 Oct 2022

Sponsor / Collaborator

Allakos, Inc.

NCT05155085

/ TerminatedPhase 2

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Lirentelimab in Adult Subjects With Moderate-to-Severe Atopic Dermatitis Inadequately Controlled by Topical Treatments

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given every 2 weeks for 7 doses, in adult subjects with moderate-to-severe AD inadequately controlled by topical treatments. Subjects who complete the randomized, double-blind, placebo-controlled treatment period may have the option to enroll in an open-label extension period and receive up to 7 doses of subcutaneous lirentelimab.

Start Date27 Jun 2022

Sponsor / Collaborator

Allakos, Inc.

NCT05152563

/ WithdrawnPhase 3

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of Subcutaneous AK002 in Subjects With Moderate to Severe Eosinophilic Gastritis and/or Eosinophilic Duodenitis

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacodynamic effect of subcutaneous lirentelimab (AK002), given monthly for 6 doses, in subjects with moderate to severe Eosinophilic Gastritis and/or Eosinophilic Duodenitis who have an inadequate response with, lost response to, or were intolerant to standard therapies.

Start Date01 Dec 2021

Sponsor / Collaborator

Allakos, Inc.

100 Clinical Results associated with Antolimab

100 Translational Medicine associated with Antolimab

100 Patents (Medical) associated with Antolimab

Literatures (Medical) associated with Antolimab

01 Mar 2026·ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Emerging IgE and non-IgE targeted therapies for chronic urticaria

Review

Author: Chhiba, Krishan D ; Saini, Sarbjit S

Chronic urticaria affects a significant percent of the global population and carries a higher burden of unmet medical need. Current standard-of-care includes antihistamines and omalizumab, but omalizumab is not effective in all patients and has not been found to induce long-term disease remission. This review evaluates the diverse therapeutic pipeline spanning IgE-based and non-IgE-based mast cell targeting strategies, including recent clinical data. The therapeutic landscape has expanded rapidly with multiple mechanisms under investigation. IgE-targeted approaches include omalizumab biosimilars, with CT-P39 having received Food and Drug Administration (FDA) approval. Dupilumab received FDA approval for antihistamine-refractory chronic spontaneous urticaria supporting the targeting of type 2 cytokines, interleukin-4, and interleukin-13, in this disease. Bruton's tyrosine kinase inhibitors have promise, with remibrutinib receiving FDA approval and demonstrating significant reductions in UAS7 in phase 3 trials. c-Kit (c-Kit or KIT) inhibition with barzolvolimab demonstrates robust efficacy with sustained effects post-treatment. Finally, Janus kinase inhibitors, Mas-related G protein-coupled receptor X2 antagonists, and other novel mechanisms are advancing through clinical trials. Although some programs have been discontinued due to safety concerns or lack of efficacy such as fenebrutinib (Bruton's tyrosine kinase inhibitor), THB001 (c-Kit inhibitor), EP262 (Mas-related G protein-coupled receptor X2 antagonist), tezepelumab (anti-TSLP), and lirentelimab and AK006 (sialic acid binding immunoglobulin-like lectin-targeting agents), these studies have informed many of the other positive studies. In summary, in the last year, we have seen the chronic urticaria pipeline mature with multiple phase 3 programs and new approvals representing diverse mechanisms of action. Nevertheless, significant therapeutic gaps persist for omalizumab-refractory disease and chronic-inducible urticaria.

01 Feb 2026·Journal of Allergy and Clinical Immunology-In Practice

Systemic Treatments for Chronic Spontaneous Urticaria: Anti-IgE and Beyond

Review

Author: Saini, Sarbjit S ; Bernstein, Jonathan A ; Hsu, Florence Ida ; Chhiba, Krishan D

Chronic urticaria, which is divided into chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), affects a significant percentage of the global population and carries a high burden of unmet medical need. Current standard of care includes nonsedating H1-antihistamines and omalizumab, which targets peripheral blood IgE and downregulates mast cell and basophil IgE receptors. However, omalizumab provides complete hive resolution in approximately 45% of patients and does not produce lasting remission. This review examines the clinical data for newly approved and emerging systemic therapies spanning IgE-based and non-IgE-based targeting strategies. The therapeutic landscape has expanded rapidly, and multiple mechanisms are under investigation. IgE-targeted approaches include omalizumab biosimilars, with CT-P39 having received Food and Drug Administration (FDA) approval. Dupilumab received FDA approval for H1-antihistamine-refractory CSU, supporting targeting type 2 cytokines, IL-4 and IL-13. Most recently, a Bruton's tyrosine kinase inhibitor (BTKi), remibrutinib, demonstrated significant reductions in Urticaria Activity Score over 7 days in phase 3 trials, leading to FDA approval. Newer c-Kit (cKit or KIT) inhibitors have also shown efficacy in CSU and CIndU, with barzolvolimab showing sustained efficacy post-treatment. Finally, other BTKi, Janus kinase (JAK) inhibitors, tyrosine kinase 2/JAK inhibitors, MRGPRX2 antagonists, and other novel mechanisms are advancing through clinical trials. Some drugs have been halted in development because of safety concerns, such as fenebrutinib (BTKi), THB001 (Larvol; c-Kit inhibitor), and EP262 (MRGPRX2 antagonist), whereas others, targeting the alarmin thymic stromal lymphopoietin (tezepelumab), the Th2 cytokine IL-5 (mepolizumab) and its receptor IL-5R (benralizumab), as well as lirentelimab (sialic acid-binding immunoglobulin-like lectin 8 [Siglec-8]) and AK006 (Siglec-6), were halted because of lack of efficacy. However, these failed trials have provided informed insights into the relevant pathways for CSU pathogenesis and treatment. In summary, systemic therapies for CSU are maturing with multiple phase 3 programs targeting the IgE pathway and Th2 cytokines leading to recent approvals. This review will provide an overview of these recently completed and ongoing clinical studies investigating emerging IgE and non-IgE therapeutic options for CSU.

01 Aug 2025·Current Opinion in Allergy and Clinical Immunology

Hypereosinophilia: clinical and therapeutic approach in 2025

Review

Author: Canalis, Silvia ; Costanzo, Giulia Anna Maria Luigia ; Taurisano, Giusi ; Ruffi, Maria Clara

Purpose of review:

This review addresses the clinical and biological complexities of hypereosinophilia (HE) and hypereosinophilic syndrome (HES), highlighting the need for improved diagnostic frameworks and therapeutic strategies. Due to the increasing recognition of HE and its potential for severe multiorgan involvement, a structured, multidisciplinary approach to diagnosis and management is essential for optimizing patient outcomes.

Recent findings:

Recent literature categorizes HE into hereditary, reactive, and neoplastic forms, with significant advancements in defining associated conditions and their pathophysiological mechanisms. Clinical manifestations range from asymptomatic eosinophilia to life-threatening complications involving the skin, lungs, gastrointestinal tract, heart, and nervous system. Corticosteroids remain the first-line treatment across most subtypes. Imatinib has shown high efficacy, particularly in patients with FIP1L1::PDGFRA fusion. However, therapeutic resistance and relapse still occur. Biologic therapies targeting interleukin (IL)-5 or its receptor, such as mepolizumab and benralizumab, have demonstrated promise in reducing eosinophils counts and preventing flare-ups. Additional agents under investigation include dupilumab and lirentelimab.

Summary:

The findings highlight the importance of accurate classification and tailored management of HE and HES, which are crucial for preventing organ damage and improving quality of life. Ongoing clinical trials and research will expand therapeutic options, clarify underlying mechanisms, and address current unmet needs.

News (Medical) associated with Antolimab

20 Aug 2025

·www.fiercebiotech.com

Celldex ends esophageal program despite hitting primary endpoint in phase 2 trial

Investors sent Celldex’s share price down by 18% to $19.72 in premarket trading.\n Celldex has stopped development of barzolvolimab in eosinophilic esophagitis (EoE) despite meeting its primary endpoint in a phase 2 trial. The biotech showed the candidate depletes mast cells in the gastrointestinal tract, but that positive finding was overshadowed by the antibody\'s failure to improve clinical outcomes.EoE is a chronic inflammatory condition of the esophagus characterized by the infiltration of eosinophils and mast cells, two types of white blood cells. Yet, efforts to treat the condition by targeting white blood cells have floundered. Allakos’ lirentelimab reduced eosinophils in a phase 2/3 trial but showed no significant effect on a dysphagia scale that assessed patients’ ability to swallow food, a key symptom of EoE.Now, Celldex has suffered a similar setback. The biotech randomized 65 patients to receive the anti-KIT antibody barzolvolimab or placebo. After 12 weeks, mucosal mast cell levels in the gastrointestinal tract had fallen significantly in the barzolvolimab cohort compared to placebo, achieving the trial’s primary endpoint. Previously, Celldex had shown the antibody can deplete cutaneous mast cells.Yet, the mucosal mast cell primary endpoint was just one of two key areas of focus for Celldex. The biotech also wanted to show that depleting mast cells improves symptoms, as Celldex CEO Anthony Marucci explained on a Tuesday call with investors to discuss the data.“We have repeatedly said that we needed to not only see profound impact of cell depletion, but we also [needed] a reduction of dysphagia scores that would be clinically meaningful and compare favorably to the current standard of care,” Marucci said. “These results did not meet our internal hurdle rate, and we will not advance development in this indication.” Scores on the Dysphagia Symptom Questionnaire were no better for patients on barzolvolimab than placebo, the biotech reported. Equally, Celldex saw no significant improvement in endoscopic scoring of EoE-related inflammation and fibrosis in the treatment group. After Celldex reported the trial findings and program discontinuation, investors sent the biotech’s share price down by 18% to $19.72 in premarket trading.Celldex is continuing to test barzolvolimab in two phase 3 trials in chronic spontaneous urticaria as well as in phase 2 studies in atopic dermatitis and prurigo nodularis. The biotech advanced in those settings on the strength of evidence that barzolvolimab depletes cutaneous mast cells. The discovery in the EoE trial that barzolvolimab also depletes mucosal mast cells could open up other indications for KIT inhibitors. The EoE trial suggests Celldex could expand beyond skin conditions to target gastrointestinal conditions where mast cells play a role. One possibility is that Celldex will apply its bispecific approach, rather than barzolvolimab, to gastrointestinal indications. Engaging two targets may unlock diseases where depleting mast cells is beneficial but insufficient to significantly improve clinical outcomes. The failures of Allakos and Celldex in EoE have thinned the field of late-stage programs in this indication. Amgen and AstraZeneca are still in the running, with a phase 3 trial of the partners’ anti-TSLP antibody Tezspire now fully enrolled. Tezspire reduces blood eosinophil counts but works in severe asthma patients irrespective of their starting levels of the white blood cells.

Phase 3Phase 2Clinical ResultImmunotherapyCell Therapy

12 Mar 2025

·www.globenewswire.com

Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results

SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter ended December 31, 2024. Recent Allakos Events Reported topline data from the Phase 1 study of AK006 in patients with chronic spontaneous urticaria in January 2025.Announced in January 2025 that the Company was discontinuing further development of AK006, restructuring operations to reduce costs and exploring strategic alternatives. Cash Guidance Allakos ended the fourth quarter of 2024 with $80.8 million in cash, cash equivalents and investments. Allakos’ financial outlook, restructuring activities and estimated cash outlook as reported by the Company in January 2025 remain unchanged. The Company estimates that cash used in restructuring activities to close out AK006 development, including severance and contractual payments to vendors, will be approximately $34 million to $38 million. The Company also estimates that a significant majority of these restructuring costs will be paid over the first and second quarters of 2025. The Company estimates it will have cash, cash equivalents and investments in a range of approximately $35 million to $40 million at June 30, 2025. Fourth Quarter 2024 Financial Results Allakos ended the fourth quarter of 2024 with $80.8 million in cash, cash equivalents and investments resulting in a net decrease in cash, cash equivalents and investments of $11.9 million during the fourth quarter of 2024. Research and development expenses were $14.8 million in the fourth quarter of 2024 compared to $53.8 million in the fourth quarter of 2023, a decrease of $39.0 million. This quarter over quarter decrease is due to halting lirentelimab development and includes a $31.2 million decrease in contract research and manufacturing costs, $6.7 million of decreased compensation costs and a $1.1 million decrease in other research and development expenses. General and administrative expenses were $9.8 million for the fourth quarter of 2024 compared to $11.2 million for the fourth quarter of 2023, a decrease of $1.4 million. The quarter over quarter change included $2.9 million of decreased compensation costs offset by a $1.5 million increase primarily from professional and other general costs associated with the termination of our office lease. Allakos reported net income of $0.4 million in the fourth quarter of 2024 compared to a net loss of $62.6 million in the fourth quarter of 2023. The gain in the fourth quarter of 2024 was primarily attributed to the $23.9 million gain on lease amendment recognized as a result of the lease termination agreement entered into during the fourth quarter of 2024. About Allakos Allakos is a clinical stage biotechnology company that has been developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, Allakos’ expectations regarding its financial position and guidance, including estimated costs of restructuring activities to close out AK006 development, the timing of payment of such restructuring costs, and estimated ending second quarter 2025 cash, cash equivalents and investments; restructuring activities and plans; and exploration of strategic alternatives. Such statements are based on Allakos’ current views about its plans, intentions, expectations, strategies and prospects only as of the date of this release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from those set forth in or implied by such forward-looking statements, including but not limited to: uncertainties related to Allakos’ ability to realize the contemplated benefits of its restructuring activities and related reduction in force; Allakos’ ability to accurately forecast financial results, including restructuring and other costs and expenses; availability of suitable third parties with which to conduct contemplated strategic alternative transactions; whether Allakos will be able to pursue strategic alternative transactions, or whether any transaction, if pursued, will be completed on attractive terms; whether Allakos’ cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; Allakos’ ability to maintain the listing of its common stock on Nasdaq; general economic and market conditions, both domestic and international; risks associated with volatility and uncertainty in the capital markets for biotechnology companies; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that Allakos files from time to time to with the SEC. These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos’ forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Allakos specifically disclaims any obligation to update any forward-looking statement, except as required by law. These forward-looking statements should not be relied upon as representing Allakos’ views as of any date subsequent to the date of this press release. Source: Allakos Inc. Investor Contact:Adam Tomasi, PresidentAlex Schwartz, VP Strategic Finance and Investor Relationsir@allakos.com Media Contact:media@allakos.com ALLAKOS INC. UNAUDITED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME AND LOSS (in thousands, except per share data) Three Months Ended Twelve Months Ended December 31, December 31, 2024 2023 2024 2023 Operating expenses Research and development $14,819 $53,801 $79,939 $150,908 General and administrative 9,837 11,182 38,822 45,148 Impairment of long-lived assets — — 27,347 — Gain on lease amendment (23,883) — (23,883) — Total operating expenses 773 64,983 122,225 196,056 Loss from operations (773) (64,983) (122,225) (196,056)Interest income 1,104 2,382 6,450 10,347 Other expense, net 45 50 (43) 8 Net income (loss) 376 (62,551) (115,818) (185,701)Unrealized gain (loss) on investments (198) 122 86 334 Comprehensive income (loss) $178 $(62,429) $(115,732) $(185,367)Net income (loss) per common share: Basic and diluted $0.00 $(0.71) $(1.30) $(2.14)Weighted-average number of common shares outstanding: Basic 89,445 87,567 88,791 86,798 Diluted 90,400 87,567 88,791 86,798 ALLAKOS INC. UNAUDITED CONDENSED BALANCE SHEETS (in thousands) December 31, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $17,753 $66,440 Investments 63,067 104,354 Prepaid expenses and other current assets 4,766 9,095 Total current assets 85,586 179,889 Property and equipment, net 10,827 33,369 Operating lease right-of-use assets — 24,136 Other long-term assets 188 6,216 Total assets $96,601 $243,610 Liabilities and stockholders’ equity Current liabilities: Accounts payable $5,490 $1,764 Accrued expenses and other current liabilities 12,294 34,814 Total current liabilities 17,784 36,578 Operating lease liabilities, net of current portion — 38,215 Total liabilities 17,784 74,793 Stockholders’ equity: Common stock 90 88 Additional paid-in capital 1,312,886 1,287,156 Accumulated other comprehensive gain (loss) 136 50 Accumulated deficit (1,234,295) (1,118,477)Total stockholders’ equity 78,817 168,817 Total liabilities and stockholders’ equity $96,601 $243,610

Financial Statement

06 Nov 2024

·www.globenewswire.com

Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results

SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2024. Recent Allakos Events Reported safety, pharmacokinetics (PK), and pharmacodynamic (PD) results from the Phase 1 trial of subcutaneous (SC) AK006 in healthy volunteers. Bioavailability of subcutaneous AK006 was approximately 77%.Subcutaneous administered AK006 showed an estimated half-life of 12-22 days.Consistent with the IV formulation, skin biopsies taken from subcutaneous AK006 treated healthy volunteers showed high levels of receptor occupancy confirming AK006 reaches skin tissue mast cells.The 720 mg dose of AK006 showed 98% receptor occupancy at day 113 suggesting the potential for infrequent dosing.Single and multiple doses of IV AK006 and single dose subcutaneous AK006 up to 720 mg were well tolerated with a favorable safety profile. Completed enrollment of over 30 patients in the randomized, double-blind, placebo-controlled Phase 1 trial of intravenous (IV) AK006 in patients with chronic spontaneous urticaria. Data from these patients expected in early Q1 of 2025. Upcoming Allakos Anticipated Milestones Report randomized double-blind, placebo-controlled data on over 30 patients from the Phase 1 trial of AK006 in patients with CSU in early Q1 of 2025. Cash Guidance Allakos ended the third quarter of 2024 with $92.7 million in cash, cash equivalents and investments. Allakos’ financial outlook, restructuring activities and estimated cash runway as reported by the Company in January 2024 remain unchanged. The Company reiterates that it expects the restructuring activities will extend the cash runway into mid-2026 and to end 2024 with total cash, cash equivalents and investments in its previously stated $81 to $86 million guidance range. The Company has substantially completed its exit of the lirentelimab development program. Third Quarter 2024 Financial Results Allakos ended the third quarter of 2024 with $92.7 million in cash, cash equivalents and investments resulting in a net decrease in cash, cash equivalents and investments of $30.4 million during the third quarter of 2024. Approximately $18 million of this third quarter decrease was paid in connection with exiting the lirentelimab development program. Research and development expenses were $10.9 million in the third quarter of 2024 compared to $36.7 million in the third quarter of 2023, a decrease of $25.8 million. This quarter over quarter decrease is attributed to $16.4 million of lower contract research and development costs, primarily due to halting lirentelimab development and includes a $4.6 million decrease relating to a change in estimated manufacturing costs upon resolution of the related work orders with the vendor, $5.7 million of decreased compensation costs and a $3.7 million decrease in other research and development expenses. General and administrative expenses were $8.9 million for the third quarter of 2024 compared to $11.5 million for the third quarter of 2023, a decrease of $2.6 million. The quarter over quarter change included $2.4 million of decreased compensation costs and $0.2 million of decreased other general and administrative expenses. Allakos reported a net loss of $18.4 million in the third quarter of 2024 compared to $45.6 million in the third quarter of 2023. Net loss per basic and diluted share was $0.21 for the third quarter of 2024 compared to $0.52 in the third quarter of 2023. About Allakos Allakos is a clinical stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. Activating these immunomodulatory receptors allows for the direct targeting of cells involved in disease pathogenesis and, in the setting of allergy and inflammation, has the potential to result in broad inhibition of inflammatory cells. The Company’s most advanced product candidate is AK006. AK006 targets Siglec-6, an inhibitory receptor expressed on mast cells. Mast cells are widely distributed in the body and play a central role in the inflammatory response. Inappropriately activated mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. In preclinical studies, AK006 appears to provide deep mast cell inhibition and, in addition to its inhibitory activity, reduce mast cell numbers. For more information, please visit the Company’s website at www.allakos.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, Allakos’ expected timing of reporting data from its clinical trial of AK006; cash guidance and runway; and restructuring. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to: Allakos’ stages of clinical drug development; Allakos’ ability to timely initiate and complete clinical trials for AK006; Allakos’ ability to obtain required regulatory approvals for its clinical trials; uncertainties related to the enrollment of patients in its clinical trials; Allakos’ ability to demonstrate sufficient safety and efficacy of its product candidates in its clinical trials; uncertainties related to the success of clinical trials, regardless of the outcomes of preclinical testing or early-stage trials; Allakos’ ability to obtain regulatory approvals to market its product candidates; market acceptance of Allakos’ product candidates; uncertainties related to the projections of the size of patient populations suffering from the diseases Allakos is targeting; Allakos’ ability to advance additional product candidates beyond AK006; uncertainties related to Allakos’ ability to realize the contemplated benefits of its restructuring and related reduction in force; Allakos’ ability to accurately forecast financial results; Allakos’ ability to obtain additional capital to finance its operations, research and drug development; Allakos’ ability to maintain the listing of our common stock on Nasdaq; general economic and market conditions, both domestic and international; domestic and international regulatory obligations; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that Allakos files from time to time to with the SEC. These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos’ forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Allakos specifically disclaims any obligation to update any forward-looking statement, except as required by law. These forward-looking statements should not be relied upon as representing Allakos’ views as of any date subsequent to the date of this press release. Source: Allakos Inc. Investor Contact:Adam Tomasi, PresidentAlex Schwartz, VP Strategic Finance and Investor Relationsir@allakos.com Media Contact:media@allakos.com ALLAKOS INC.UNAUDITED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(in thousands, except per share data) Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Operating expenses Research and development $10,874 $36,749 $65,120 $97,107 General and administrative 8,876 11,461 28,985 33,966 Impairment of long-lived assets — — 27,347 — Total operating expenses 19,750 48,210 121,452 131,073 Loss from operations (19,750) (48,210) (121,452) (131,073)Interest income 1,392 2,590 5,346 7,965 Other expense, net (14) (6) (88) (42)Net loss (18,372) (45,626) (116,194) (123,150)Unrealized gain (loss) on investments 325 87 284 212 Comprehensive loss $(18,047) $(45,539) $(115,910) $(122,938)Net loss per common share: Basic and diluted $(0.21) $(0.52) $(1.31) $(1.42)Weighted-average number of commonshares outstanding: Basic and diluted 89,024 87,115 88,571 86,539 ALLAKOS INC.UNAUDITED CONDENSED BALANCE SHEETS(in thousands) September 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $10,449 $66,440 Investments 82,266 104,354 Prepaid expenses and other current assets 4,438 9,095 Total current assets 97,153 179,889 Property and equipment, net 15,733 33,369 Operating lease right-of-use assets 9,880 24,136 Other long-term assets 1,668 6,216 Total assets $124,434 $243,610 Liabilities and stockholders’ equity Current liabilities: Accounts payable $3,964 $1,764 Accrued expenses and other current liabilities 12,017 34,814 Total current liabilities 15,981 36,578 Operating lease liabilities, net of current portion 35,710 38,215 Total liabilities 51,691 74,793 Stockholders’ equity: Common stock 89 88 Additional paid-in capital 1,306,991 1,287,156 Accumulated other comprehensive gain (loss) 334 50 Accumulated deficit (1,234,671) (1,118,477) Total stockholders’ equity 72,743 168,817 Total liabilities and stockholders’ equity $124,434 $243,610

Financial StatementPhase 1Clinical Result

100 Deals associated with Antolimab

External Link

KEGG	Wiki	ATC	Drug Bank
-	Antolimab	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastritis	Phase 3	United States	Allakos, Inc.	01 Dec 2021
Eosinophilic Esophagitis	Phase 3	United States	Allakos, Inc.	06 Jul 2020
Eosinophilic Esophagitis	Phase 3	Australia	Allakos, Inc.	06 Jul 2020
Eosinophilic Esophagitis	Phase 3	Netherlands	Allakos, Inc.	06 Jul 2020
Eosinophilic Duodenitis	Phase 3	United States	Allakos, Inc.	18 Jun 2020
Eosinophilic Enteropathy	Phase 3	United States	Allakos, Inc.	18 Jun 2020
Moderate Atopic Dermatitis	Phase 2	United States	Allakos, Inc.	27 Jun 2022
Moderate Atopic Dermatitis	Phase 2	Germany	Allakos, Inc.	27 Jun 2022
Severe Atopic Dermatitis	Phase 2	United States	Allakos, Inc.	27 Jun 2022
Severe Atopic Dermatitis	Phase 2	Germany	Allakos, Inc.	27 Jun 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05528861 (MAVERICK, CTgov)	Phase 2	Chronic Urticaria	127	AK002 (AK002 SC 300 mg (Main Study))	yugnduifrk(udlylyania) = ngdjjuwcbb ofmyyvzmvq (ljfllihogj, 1.9) View more	-	27 Sep 2024
				Placebo (Placebo (Main Study))	yugnduifrk(udlylyania) = qfoznravhl ofmyyvzmvq (ljfllihogj, 2.0) View more
NCT05155085 (ATLAS, CTgov)	Phase 2	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	131	AK002 (AK002 SC 300 mg (Main Study))	mdmyhhrafc = uxqpkhacsq lfknxndqvk (phdgefllgj, uhiofezloi - jlvwppzzfa) View more	-	24 Sep 2024
				Placebo (Placebo (Main Study))	mdmyhhrafc = fecquvhqcf lfknxndqvk (phdgefllgj, buuoiwkkks - exgaskutjy) View more
NCT04620811 (CTgov)	Phase 3	Eosinophilic Enteropathy \| Eosinophilic Duodenitis	159	Lirentelimab (AK002) (Main Study Placebo to Extension Study 3.0 mg/kg of Lirentelimab (AK002))	bdxeogjpbw = gsivjjbcvz ymchxtdugm (tfjpewtmsi, cmopfonvgo - vwzamshjio) View more	-	18 Apr 2024
				Lirentelimab (Main Study Active to Extension Study 3.0 mg/kg of Lirentelimab (AK002))	bdxeogjpbw = bgehionkeq ymchxtdugm (tfjpewtmsi, hijwizbclm - zzvbscfoqx) View more
NCT03664960 (CTgov)	Phase 2	Eosinophilic Enteropathy \| Eosinophilic Duodenitis	58	Placebo+AK002 (Main Study Placebo to Extension Study 1 to 3.0 mg/kg of AK002)	ngsitgwfat = hcuvexlaib hqiyuanyva (xxonjbzktw, pxzcqnxece - gjlfoovjlh) View more	-	28 Feb 2024
				AK002 (Main Study Active to Extension Study 1 to 3.0 mg/kg of AK002)	ngsitgwfat = fkitwverzd hqiyuanyva (xxonjbzktw, qqqalmjoow - tgrxllosls) View more
NCT03496571 (ENIGMA, CTgov)	Phase 2	Eosinophilic Enteropathy	65	AK002 (1 mg/kg of AK002)	hizlfiqmcp(yodvkpljjj) = dwfugnfxim uhlwdzrwar (dehacevpjq, cosnrfefwe - apxtlxdcjr) View more	-	17 Jan 2024
				AK002 (3 mg/kg of AK002)	hizlfiqmcp(yodvkpljjj) = hdjurcggao uhlwdzrwar (dehacevpjq, urkfdwhkqt - jbljkhjiqv) View more
NCT05528861 (MAVERICK, GlobeNewswire) Manual	Phase 2	Chronic Urticaria	123	Lirentelimab	kutmincsqq(cmidkungpj) = kjtmfryjkq rvpefaeino (hrsdyzjylz ) View more	Negative	16 Jan 2024
				Placebo	kutmincsqq(cmidkungpj) = wtxlefrhel rvpefaeino (hrsdyzjylz ) View more
NCT05155085 (ATLAS, GlobeNewswire) Manual	Phase 2	Dermatitis, Atopic	122	Lirentelimab	jfjwdleuls(hzocooifgn) = osxqjxeqfg rpqeegmynp (fnbotyeqyh ) Not Met View more	Negative	16 Jan 2024
				Placebo	jfjwdleuls(hzocooifgn) = rpscvkdwra rpqeegmynp (fnbotyeqyh ) Not Met View more
NCT04322604 (ENIGMA 2, CTgov)	Phase 3	Eosinophilic Enteropathy \| Eosinophilic Duodenitis	181	lirentelimab (AK002) (3 mg/kg of Lirentelimab (AK002))	minuyahddf = imzrpmecyd fidggliigx (cbqwoqqrsf, icpcwekrrg - cuxqtdvzbn) View more	-	02 Jan 2024
				Placebo (Placebo)	minuyahddf = ahcmqvjpmh fidggliigx (cbqwoqqrsf, tlzicwhriu - ciepvizapg) View more
NCT04322708 (KRYPTOS, CTgov)	Phase 2/3	Eosinophilic Esophagitis	277	lirentelimab (AK002) (1 mg/kg of Lirentelimab (AK002))	sohgmbihmd = eoizieyhew fpdtatvgui (mdcysudaqr, qtogscjdpm - cpipnqgdrz) View more	-	02 Jan 2024
				lirentelimab (AK002) (3 mg/kg of Lirentelimab (AK002))	sohgmbihmd = opytvukpjo fpdtatvgui (mdcysudaqr, srgxbaapeh - vyhvgjkwsx) View more
NCT04856891 (EoDyssey, CTgov)	Phase 3	Eosinophilic Enteropathy \| Eosinophilic Duodenitis	94	AK002 (3.0 mg/kg of Lirentelimab (AK002))	xdxxiezsgl = hmgnqkpbbc lruudgujro (hhcqcyfigi, mnyhprffbx - tigilacizr) View more	-	02 Jan 2024
				Placebo (Placebo)	xdxxiezsgl = jucuposyte lruudgujro (hhcqcyfigi, kzfundxvqu - vmnkgsbjji) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis